

Special Issue

The Role of Immune Cells in the Tumor Microenvironment

Message from the Guest Editor

For several years now, with the emergence of immunotherapy, the role of immune cells in tumor progression has gained more and more attention. We have learnt that immune cells are key actors of treatment resistance, and the re-establishment of an immunocompetent microenvironment is a therapeutic challenge. The role of immune cells in tumor progression is nevertheless complex and bivalent depending on the local tumor microenvironment. We need now to go further and to better identify the role of immune cell subsets to propose new therapeutic strategies. We also know that immune cells and tumor vascularization are closely related, as are immune cells and tumor stem cells. Particular attention will address the cross talk between tumor stem cells and immune cells, as well as tumor vascularization and immune cells. Furthermore, brain tumors have a specific immune environment with the presence of local immune cells, such as microglia cells. Strong connections exist between microglia cells and astrocytes supporting and promoting immunosuppression. Therefore, to better understand immune brain microenvironment, studies dealing with brain tumors are welcome.

Guest Editor

Dr. Aurélie Tchoghandjian

Institute of Neurophysiopathology, Aix-Marseille University, CNRS, INP, 13005 Marseille, France

Deadline for manuscript submissions

closed (31 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/88989

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)